Corvus Pharmaceuticals, Inc. (C17.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 08:05AM CEST
| Previous Close | 1.4420 |
| Open | 1.5620 |
| Bid | 0.0000 x 40000 |
| Ask | 0.0000 x 40000 |
| Day's Range | 1.5620 - 1.5620 |
| 52 Week Range | 0.9600 - 3.5600 |
| Volume | |
| Avg. Volume | 1 |
| Market Cap | 79.158M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Zacks
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Zacks
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
© 2024 Yahoo. All rights reserved.